Darren Snellgrove was named Chief Financial Officer of Halozyme Therapeutics, Inc., effective June 8, 2026. As of November 6, 2026, Halozyme Therapeutics, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 30, 2026 to September 30, 2026, naming 3 appointments (Form 8-K, April 30, 2026).
Who owns Halozyme Therapeutics Inc?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Halozyme Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: James Daly · 8-K, 2026-09-30
- · In / out: In · Person: Dannielle Appelhans · 8-K, 2026-08-18
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-02
- · In / out: In · Person: Darren Snellgrove · Role: Chief Financial Officer · Effective: 2026-06-08 · 8-K, 2026-04-30
Halozyme Therapeutics, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-30 to 2026-09-30. They name 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as Halozyme Therapeutics, Inc. files it.
Also on the record for Halozyme Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.21% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 10.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Halozyme Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Halozyme Therapeutics, Inc. and the records around it.
Halozyme Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Halozyme Therapeutics, Inc.
Get an email when Halozyme Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Halozyme Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Halozyme Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Halozyme Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-30 | In | 8-K, 2026-09-30 | |||
| 2026-08-18 | In | 8-K, 2026-08-18 | |||
| 2026-07-02 | Reported | not named in the filing | 8-K, 2026-07-02 | ||
| 2026-04-30 | In | Chief Financial Officer | 2026-06-08 | 8-K, 2026-04-30 |
Who leads Halozyme Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Darren Snellgrove, appointed, effective 2026-06-08 (filed 2026-04-30).
New leaders reset buying decisions — get the Full Report on Halozyme Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Halozyme Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Halozyme Therapeutics, Inc.Every change, in the filing's words
Appointed: James Daly
(d) On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the "Company").
- Mr. Daly was elected to the class of directors with terms ending at the Company's annual meeting of stockholders in 2029 and was not initially assigned to any Board committee.
- Mr. Daly will receive compensation for his services (currently consisting of cash retainers for Board and committee service, restricted stock and stock option awards) under our director compensation program applicable to all non-employee directors, as revised from time to time.
Appointed: Dannielle Appelhans
(d) On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the "Company").
- Ms. Appelhans was elected to the class of directors with terms ending at the Company's annual meeting of stockholders in 2028 and was not initially assigned to any Board committee.
- Ms. Appelhans will receive compensation for her services (currently consisting of cash retainers for Board and committee service, restricted stock and stock option awards) under our director compensation program applicable to all non-employee directors, as revised from time to time.
- The current components of the non-employee director compensation program were described in our proxy statement for the 2026 Annual Meeting of Stockholders held on May 5, 2026.
Reported
The company also announced the departure of Cortney Caudill as the Company's Senior Vice President, Chief Operating Officer.
- (b) On June 30, 2026, Halozyme Therapeutics, Inc. (the "Company") announced an update to its senior management structure.
- The Company would like to thank Ms. Caudill for her contributions during her tenure with the Company.
Appointed: Darren Snellgrove, Chief Financial Officer, effective 2026-06-08
(c) On April 30, 2026, Halozyme Therapeutics, Inc. (the "Company") announced that Darren Snellgrove has been appointed to serve as the Company's Chief Financial Officer ("CFO"), effective June 8, 2026.
- Since May 2025, Mr. Snellgrove (age 52) has served as Vice President, Investor Relations at Johnson & Johnson, a multinational pharmaceutical, biotechnology and medical technologies corporation ("J&J").
- From August 2021 to May 2025, he served as the CFO of J&J's Pharmaceutical sector.
- Previously he served in other finance leadership positions at J&J, including as CFO, VP Finance and Operations Pharmaceutical R&D from 2017 to August 2021, and as CFO, J&J Innovation from 2013 to 2017.
- Prior to 2013, Mr. Snellgrove served in other positions of increasing responsibility at J&J, including serving as CFO, Janssen Alzheimer Immunotherapy.
- Mr. Snellgrove holds a B.A. Honors Degree in Economics and Philosophy from Southampton University, England and an M.B.A. from Villanova University.
- Effective as of June 8, 2026, David Ramsay, the Company's current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.
- In his role as CFO, Mr. Snellgrove will be paid an annual salary of $670,000 and he will be eligible to participate in the Company's executive officer incentive plans, with a bonus target equal to 50% of his base salary, which will be prorated in 2026.
Tools for this story
Each opens in a new tab, filled in for Halozyme Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.